China have a breakthrough therapy process like the USA. This was established in 2020 by the China National Medical Products Administration (NMPA).
Bisantrene solves a problem with unmet clinical need while also improving cancer outcomes for patients. If the human data confirms circumstantial and preclinical evidence, then I think Bisantrene could be a cash generating asset much sooner than expected.
Ann: First Patient Safely Combine Dosed in Phase 1 RC220 Trial, page-147
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.015(1.24%) |
Mkt cap ! $212.8M | |||
| Open | High | Low | Value | Volume |
| $1.23 | $1.24 | $1.18 | $129.9K | 107.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 912 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4775 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| RAC (ASX) Chart |